Biogen awaits Medicare decision on Alzheimer’s drug amid public pressure for coverage
travellinglight/iStock via Getty Images

Patient advocacy groups in the U.S. have stepped up their efforts for a favorable decision on the coverage for Aduhelm and similar Alzheimerâs drugs as the developers await a final decision next month.
Backed by millions of dollars in ad spending, local adverts have already come up during the Sunday morning political shows, and a public protest is scheduled for this week, Reuters reported Sunday.
In January, the Centers for Medicare & Medicaid Services (CMS) proposed to severely restrict access to a group of Alzheimerâs medications, designed to target the amyloid plaques of patientsâ brains, only for those undergoing clinical studies. A final determination on coverage is scheduled for April 11.
The decision applies to not only Aduhelm but also other Alzheimerâs drugs currently being developed by Eli Lilly (NYSE:LLY) and Roche (OTCQX:RHHBY).
The proposal followed the U.S. approval of Aduhelm developed by Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALY)
(OTCPK:ESALF), which led to widespread criticism last year.
USAgainstAlzheimer's, one of the biggest patient advocacy groups for Alzheimerâs in the U.S., has said it is funding adverts in the Washington D.C. and Baltimore areas targeting the CMS, the Department of Health and Human Services (HHS), the White House, and Congress.
"We want to put a face on the individuals that are affected by this Medicare decision," USAgainstAlzheimer's Chairman George Vradenburg said, adding that the group plans to spend millions in the campaign.
The program, featuring Alzheimer's patients, is set to run on social media, print ads on bus stops, and other transportation in the Washington area, with many having the tagline, "Alzheimer's patients can't wait."
Meanwhile, the Alliance for Aging Research has organized a protest where patients, caregivers, and others will gather near HHS headquarters in Washington on Tuesday to pressure Medicare to reconsider the decision.
Soon after the proposal in January, Biogen (BIIB) sought the support of doctors and patient advocates to send public submissions in support of a less restrictive coverage decision.